Innovative Pharmaceutical Biotech Limited reported earnings results for the full year ended March 31, 2023. For the full year, the company reported sales was HKD 8.08 million compared to HKD 11.15 million a year ago. Net loss was HKD 245.7 million compared to net income of HKD 45.8 million a year ago.

Basic loss per share from continuing operations was HKD 0.1678 compared to basic earnings per share from continuing operations of HKD 0.0313 a year ago. Diluted loss per share from continuing operations was HKD 0.1678 compared to HKD 0.0359 a year ago.